Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK+) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced AL...

Full description

Bibliographic Details
Main Authors:	Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse
Format:	Article
Language:	English
Published:	European Respiratory Society 2018-02-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/4/1/00058-2017.full

Similar Items

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
by: Peng Gao, et al.
Published: (2022-02-01)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
by: Zhongxing Bing, et al.
Published: (2021-07-01)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
by: Herbert H. Loong, et al.
Published: (2020-11-01)

Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
by: Kyaw Zwar Myint, et al.
Published: (2024-02-01)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
by: Liu M, et al.
Published: (2019-10-01)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
by: Burns MW, et al.
Published: (2015-05-01)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
by: Xia Luo, et al.
Published: (2022-09-01)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
by: Giroux Leprieur E, et al.
Published: (2016-06-01)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
by: Chih-Hsi Scott Kuo, et al.
Published: (2021-03-01)

Neoadjuvant ceritinib treatment in ALK‐rearranged locally advanced adenosquamous carcinoma: A case report
by: Shixiong Mai, et al.
Published: (2022-08-01)

ALK-driven tumors and targeted therapy: focus on crizotinib
by: Murga-Zamalloa C, et al.
Published: (2014-03-01)

A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance
by: Xin Li, et al.
Published: (2024-02-01)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
by: Matthew S. Lara, BS, et al.
Published: (2022-12-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Crystallization Behavior of Ceritinib: Characterization and Optimization Strategies
by: Iva Zokić, et al.
Published: (2023-09-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
by: Ullas Batra, et al.
Published: (2020-12-01)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
by: El-Osta H, et al.
Published: (2015-09-01)

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
by: Karim Amrane, et al.
Published: (2021-09-01)

Modification of Ceritinib Crystal Morphology via Spherical Crystallization
by: Iva Zokić, et al.
Published: (2024-11-01)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
by: Hui Li, et al.
Published: (2022-08-01)

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer
by: Yuke TIAN, et al.
Published: (2020-08-01)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
by: Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, et al.
Published: (2021-03-01)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
by: Joelle C. Boulos, et al.
Published: (2021-11-01)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
by: Wenyu Shi
Published: (2023-08-01)

Stimulation of Suicidal Erythrocyte Death by Ceritinib-Treatment of Human Erythrocytes
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2016-12-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
by: Ahmed Badran, et al.
Published: (2023-08-01)

Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
by: Elodie Mussat, et al.
Published: (2016-03-01)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
by: Christabel Wilson, et al.
Published: (2017-10-01)

Successful Conversion Surgery after Ceritinib Monotherapy in a Patient with Advanced Inflammatory Myofibroblastic Tumor Harboring SQSTM1-ALK fusion
by: Qi-An Wang, et al.
Published: (2024-06-01)

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
by: Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, et al.
Published: (2024-09-01)

Ceritinib is a novel triple negative breast cancer therapeutic agent
by: Shengli Dong, et al.
Published: (2022-06-01)

The efficacy of ceritinib in patients with -positive non-small cell lung cancer
by: John Kaczmar, et al.
Published: (2015-10-01)

Inhibition of Collagen Related Peptide Induced Platelet Activation and Apoptosis by Ceritinib
by: Hang Cao, et al.
Published: (2018-02-01)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
by: Haruka Fujita, et al.
Published: (2020-05-01)

EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
by: A. S. Mansfield, et al.
Published: (2022-03-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)